See FY25 operating cash flow $280M-$310M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals reports Q4 adjusted EPS 12c, consensus 15c
- Amneal Pharmaceuticals sees FY25 adjusted EPS 65c-75c, consensus 71c
- AMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
- Robust Growth and Strategic Positioning Drive Buy Rating for Amneal Pharmaceuticals